Clinical Trial

A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer

Name: A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer — clinical trial record (NCT06879041)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

The main purpose of the study is to assess the safety and tolerability of AZD2284, AZD2287, and AZD2275.

Protocol Amendment History 2 changes

notable Enrollment increased: 95 -> 136 participants 2026-05-13

minor Trial arms changed: 10 -> 9 2026-05-13

Trial Details

NCT Number	NCT06879041
Lead Sponsor	AstraZeneca Collaborators: Parexel
Conditions	Metastatic Castration-Resistant Prostate Cancer
Enrollment	136 participants
Start Date	2025-03-10
Primary Completion	2029-04-16 (estimated)
Study Completion	2029-04-16 (estimated)
Updated on ClinicalTrials.gov	2026-05-12